AAROGYAM works in the biotechnology and immunotherapy field, which results in development of Anti-CTLA-4. The target market includes: Drug makers chasing immune therapy breakthroughs. Laboratories developing immune modulation and cancer therapy. Healthcare Providers looking at new and evolved therapeutic solutions. Investors & Biotech Startups in search of disruptive technologies.
"Biotech: It’s More Than Just Science" The cash to drive the biotech transformation requires strategic financial planning. Key funding sources include: VC – Short for Venture Capital Firms (Investors in biotech innovations). Government Grants – Programs such as NIH’s SBIR & STTR grants help get biotech startups off the ground. Corporate Contacts – Partnerships with pharmaceutical companies research grants. Angel Investors – Individuals who have contributed to early stage biotech companies. Crowdfunding & Public Cash – Financing options with biotech-specific platforms.
Top Partners: Pharma companies, research institutions, biotech investors. Key Areas: Immunotherapy research, experimental protocols and clinical use. Value Proposition: Progressing immune modulation through Anti-CTLA-4 research. Customer Segments: Healthcare providers, Bio-tech companies, Research labs. Revenue streams: Grants, partnerships, licensing biotech ѕоlutiоnѕ Channels: Internet site, scientific publications, industry exhibitions Cost Structure: R&D, lab and regulatory expenses